Loading cancer entity…
Loading cancer entity…
Clinical trials
285 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (39)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01116648 | Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 155 | National Cancer Institute (NCI)NIH | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07693452 | Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms | recruiting | Phase 2 | 15 | University of California, IrvineOTHER | 1 | Jul 13, 2026 |
| clinicaltrials |
| NCT03587311 | Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 2 | 96 | National Cancer Institute (NCI)NIH | 2 | Jul 8, 2026 | clinicaltrials |
| NCT04214067 | Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer | active not recruiting | Phase 3 | 164 | National Cancer Institute (NCI)NIH | 2 | Jul 2, 2026 | clinicaltrials |
| NCT07436793 | Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial | recruiting | Phase 2 | 140 | New Mexico Cancer Research AllianceOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07665684 | Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer(SONIC) | not yet recruiting | Phase 1 / Phase 2 | 67 | University Health Network, TorontoOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT05639972 | E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers | recruiting | Phase 1 / Phase 2 | 15 | Christian HinrichsOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05686226 | E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | recruiting | Phase 2 | 20 | Christian HinrichsOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07107334 | A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia | recruiting | Phase 2 | 20 | University of FloridaOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT06730347 | A Study of Lorigerlimab in Participants With Advanced Solid Tumors | recruiting | Phase 2 | 80 | MacroGenicsINDUSTRY | 3 | Jun 2, 2026 | clinicaltrials |
| NCT07454642 | AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors(FOCUS-01) | recruiting | Phase 1 | 174 | Avacta Life Sciences LtdINDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| NCT01167712 | Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | active not recruiting | Phase 3 | 692 | National Cancer Institute (NCI)NIH | 3 | May 29, 2026 | clinicaltrials |
| NCT03008408 | A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma | active not recruiting | Phase 2 | 90 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05049538 | Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers | recruiting | — | 1,000 | M.D. Anderson Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06466382 | OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy(OVPrecision) | recruiting | N/A | 60 | Swiss GO Trial GroupNETWORK | 1 | May 5, 2026 | clinicaltrials |
| NCT05440760 | Using Virtual Reality Technology to Improve Patient Experience and Quality of Care During Brachytherapy | recruiting | N/A | 20 | University of ArkansasOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07062016 | Molecular and ctDNA Characterization of High-Risk Endometrial Cancer | recruiting | — | 100 | Mayo ClinicOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07276360 | Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda(HypoRTCx-UG) | recruiting | Phase 2 | 278 | Uganda Cancer InstituteOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT04919629 | APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion | recruiting | Phase 2 | 60 | Roswell Park Cancer InstituteOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT05500391 | Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring(SUR-CAN) | recruiting | Phase 2 | 88 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT03875820 | Phase I Trial of Defactinib and VS-6766.(FRAME) | active not recruiting | Phase 1 | 87 | Institute of Cancer Research, United KingdomOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT06513065 | Study to Evaluate the Non-inferiority of Low-dose HIPEC Versus High-dose HIPEC in the Treatment of PMP (HIPEC-PMP)(HIPEC-PMP) | recruiting | Phase 3 | 176 | University of SouthamptonOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT07378371 | Proactive Temperature Management in CRS-HIPEC for Prevention of Delirium | not yet recruiting | N/A | 174 | Aerospace Center HospitalOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT05542407 | ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer | recruiting | Phase 1 | 58 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT04024917 | Impact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal Carcinosis(COCOON) | recruiting | N/A | 60 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07341360 | Pseudovax - A Cancer Vaccine for Patients With Pseudomyxoma Peritonei(Pseudovax) | recruiting | Early Phase 1 | 10 | Oslo University HospitalOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07328737 | One vs Three HIPEC Cycles After CRS for Pseudomyxoma Peritonei | recruiting | N/A | 132 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT05504252 | METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin(METIMMOX-2) | active not recruiting | Phase 2 | 80 | University Hospital, AkershusOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT00565851 | Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 3 | 1,052 | National Cancer Institute (NCI)NIH | 3 | Dec 30, 2025 | clinicaltrials |
| NCT06690775 | CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. | recruiting | Phase 2 | 230 | TORL Biotherapeutics, LLCINDUSTRY | 12 | Dec 23, 2025 | clinicaltrials |
| NCT03422198 | Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer(SAVE) | recruiting | Phase 3 | 188 | University of UtahOTHER | 1 | Dec 12, 2025 | clinicaltrials |
| NCT05973487 | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors | active not recruiting | Phase 1 | 840 | TScan Therapeutics, Inc.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT04111978 | MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)(MATAO) | recruiting | Phase 3 | 540 | Swiss GO Trial GroupNETWORK | 3 | Sep 29, 2025 | clinicaltrials |
| NCT07153952 | RT for Adenocarcinoma/Adenosquamous Carcinoma | active not recruiting | Phase 1 / Phase 2 | 60 | Peking Union Medical College HospitalOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07141186 | QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody Therapy | not yet recruiting | Phase 2 | 50 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Aug 26, 2025 | clinicaltrials |
| NCT07028242 | Ultrasound and Histology in AEH and Early EEC Treated Conservatively(ULTRA-SAFE) | not yet recruiting | — | 50 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jun 19, 2025 | clinicaltrials |
| NCT03201861 | Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women | recruiting | Phase 3 | 762 | RenJi HospitalOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT06805864 | Pembrolizumab Concurrent With and Following Carbon-ion Radiotherapy for Locally Advanced Cervical Adenocarcinoma(BROTHER) | not yet recruiting | Phase 2 | 45 | Gunma UniversityOTHER | 1 | Feb 3, 2025 | clinicaltrials |
| NCT06800391 | Metronomic Neoadjuvant Capecitabine and Cyclophosphamide in HUGE Pseudomyxoma Peritonei Patients(REVERSE) | recruiting | Phase 2 | 31 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06783153 | Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients | not yet recruiting | Phase 1 / Phase 2 | 80 | Mansoura UniversityOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06278857 | SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr)(SATELLITE) | recruiting | Phase 2 | 10 | Queensland Centre for Gynaecological CancerOTHER_GOV | 1 | Dec 3, 2024 | clinicaltrials |
| NCT02387203 | Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin | active not recruiting | Phase 2 | 80 | Mercy Medical CenterOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT05403554 | A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers | recruiting | Phase 1 | 70 | Light Chain Bioscience - Novimmune SAINDUSTRY | 2 | Oct 29, 2024 | clinicaltrials |
| NCT05215574 | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 130 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT01686126 | Improving the Treatment for Women With Early Stage Cancer of the Uterus(feMMe) | active not recruiting | Phase 2 | 165 | Queensland Centre for Gynaecological CancerOTHER_GOV | 2 | Aug 28, 2024 | clinicaltrials |
| NCT05080556 | Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer(ACTOv) | recruiting | Phase 2 | 80 | University College, LondonOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT05613283 | Primary Cervical Cancer Screening by Self-sampling HPV Test(PREVENT) | active not recruiting | — | 17,875 | Peking University People's HospitalOTHER | 1 | Dec 21, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jul 14, 2026source: clinicaltrials